Jingyi Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jingyi Li has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Mengmeng Li
Department of Dermatology West China Hospital, Sichuan University Chengdu China
5 shared publications - Jianzhong Zhang
Harbin Engineering University
3 shared publications Mengmeng Li
Department of Dermatology and Venereology, West China Hospital of Sichuan University
3 shared publications- Qingfeng Liu
Department of Dermatology and Venereology, West China Hospital of Sichuan University, No.37 Guo Xue Lane, Chengdu 610041, China
3 shared publications - Wei Li
Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital Sichuan University Chengdu Sichuan China
3 shared publications - Zai-Pei Guo
Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China
3 shared publications
Latest Publications
- 2 September 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
52‐week ivarmacitinib in moderate‐to‐severe atopic dermatitis: A phase 3 trial
Background: Ivarmacitinib, an oral JAK1 inhibitor, improved efficacy outcomes versus placebo at Week 16 in a phase 3 trial in patients with moderate‐to‐severe atopic dermatitis (AD). Objectives: To describe efficacy and safety outcomes through Week 52. Methods: In this multicentre, double‐blind, phase 3 trial (NCT04875169), patients aged 12–75 years were randomized 1:1:1 to receive once‐daily oral ivarmacitinib 4 mg, ivarmacitinib 8 mg, or placebo for 16 weeks, followed by a 36‐week double‐blind extension. At Week 16, placebo‐treated patients who continued in the study were re‐randomized to ivarmacitinib 4 mg or 8 mg. Key Week 52 endpoints included Investigator's Global Assessment (IGA) 0/1 with at least a 2‐grade improvement, Eczema Area and Severity Index 75 (EASI‐75), and Worst Itch Numeric Rating Scale (WI‐NRS) response. Results: Of 336 randomized patients, 258 completed 52 weeks of treatment. Among patients initially randomized to ivarmacitinib, Week 52 IGA responses were achieved by 42.3% and 40.2% of patients in the 4 mg and 8 mg groups, respectively. EASI‐75 responses were achieved by 60.6% and 55.9%, and WI‐NRS responses by 59.6% and 45.1%, respectively. During the active‐treatment period, treatment‐emergent adverse events (TEAEs) occurred in 87.5% and 85.5% of patients in the 4 mg and 8 mg groups, respectively. The most frequent TEAEs were upper respiratory tract infection, COVID‐19, SARS‐CoV‐2 test positive, and increased blood creatine phosphokinase. Serious TEAEs occurred in 5.6% and 4.4% of patients, respectively. Conclusion: Ivarmacitinib was associated with generally maintained improvement through Week 52, with a safety profile generally consistent with that observed during the placebo‐controlled period. Because the extension phase had no placebo control after Week 16, long‐term efficacy findings should be interpreted as descriptive.
- 2 September 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
52‐week ivarmacitinib in moderate‐to‐severe atopic dermatitis: A phase 3 trial
Background: Ivarmacitinib, an oral JAK1 inhibitor, improved efficacy outcomes versus placebo at Week 16 in a phase 3 trial in patients with moderate‐to‐severe atopic dermatitis (AD). Objectives: To describe efficacy and safety outcomes through Week 52. Methods: In this multicentre, double‐blind, phase 3 trial (NCT04875169), patients aged 12–75 years were randomized 1:1:1 to receive once‐daily oral ivarmacitinib 4 mg, ivarmacitinib 8 mg, or placebo for 16 weeks, followed by a 36‐week double‐blind extension. At Week 16, placebo‐treated patients who continued in the study were re‐randomized to ivarmacitinib 4 mg or 8 mg. Key Week 52 endpoints included Investigator's Global Assessment (IGA) 0/1 with at least a 2‐grade improvement, Eczema Area and Severity Index 75 (EASI‐75), and Worst Itch Numeric Rating Scale (WI‐NRS) response. Results: Of 336 randomized patients, 258 completed 52 weeks of treatment. Among patients initially randomized to ivarmacitinib, Week 52 IGA responses were achieved by 42.3% and 40.2% of patients in the 4 mg and 8 mg groups, respectively. EASI‐75 responses were achieved by 60.6% and 55.9%, and WI‐NRS responses by 59.6% and 45.1%, respectively. During the active‐treatment period, treatment‐emergent adverse events (TEAEs) occurred in 87.5% and 85.5% of patients in the 4 mg and 8 mg groups, respectively. The most frequent TEAEs were upper respiratory tract infection, COVID‐19, SARS‐CoV‐2 test positive, and increased blood creatine phosphokinase. Serious TEAEs occurred in 5.6% and 4.4% of patients, respectively. Conclusion: Ivarmacitinib was associated with generally maintained improvement through Week 52, with a safety profile generally consistent with that observed during the placebo‐controlled period. Because the extension phase had no placebo control after Week 16, long‐term efficacy findings should be interpreted as descriptive.
- Open Access
- 28 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1811041
First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity
Purpose: Type 2 chronic inflammatory diseases (e.g., atopic dermatitis and allergic rhinitis) impose a substantial global burden with unmet medical needs. Thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13) are key pathogenic drivers, and bispecific antibodies targeting both cytokines may offer synergistic clinical benefits. CM512 is a novel recombinant bispecific antibody targeting both TSLP and IL-13 with high affinity. This first-in-human, randomized, double-blind, placebo-controlled phase 1 study evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single (SAD) and multiple ascending doses (MAD) of subcutaneous CM512 in healthy adults. Methods: The SAD phase enrolled 40 healthy participants across four sequential cohorts (150, 450, 900, and 1200 mg), randomized 4:1 to receive subcutaneous CM512 or placebo per cohort. The MAD phase enrolled 24 participants across two sequential cohorts (150 and 600 mg biweekly), randomized 2:1 per cohort. The primary endpoint was safety and tolerability; secondary endpoints included PK, PD, and immunogenicity. Results: CM512 was well tolerated. Treatment-emergent adverse events (TEAEs) occurred in 71.9% (23/32) and 68.8% (11/16) of CM512 recipients in the SAD and MAD phases, with incidence comparable to placebo. All treatment-related TEAEs were mild or moderate. No serious adverse events, TEAEs leading to withdrawal, or deaths were reported. In the SAD phase, CM512 displayed linear, dose-proportional PK from 150–1200 mg, accompanied by a long terminal half-life (mean range: 58.7-73.6 days). In the MAD phase, biweekly administration resulted in accumulation (mean accumulation ratio: 2.50-3.17), consistent with its long half-life. CM512 significantly reduced free TSLP and IL-13, and sustainedly lowered blood eosinophils, IgE, and thymus activation-regulated chemokine (TARC) levels versus placebo. The incidence of treatment-emergent anti-drug antibodies in healthy participants receiving CM512 was low, at 3.1% (1/32) in the SAD phase and 0% (0/16) in the MAD phase, respectively. Conclusion: CM512 demonstrated favorable safety, linear PK, and low immunogenicity in healthy participants. It significantly reduced free target cytokines and type 2 inflammation biomarkers, supporting further clinical investigation for type 2 inflammatory diseases. Clinical trial registration: https://clinicaltrials.gov/ , identifier NCT06553209.
- 28 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1811041
Open AccessFirst-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity
Purpose: Type 2 chronic inflammatory diseases (e.g., atopic dermatitis and allergic rhinitis) impose a substantial global burden with unmet medical needs. Thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13) are key pathogenic drivers, and bispecific antibodies targeting both cytokines may offer synergistic clinical benefits. CM512 is a novel recombinant bispecific antibody targeting both TSLP and IL-13 with high affinity. This first-in-human, randomized, double-blind, placebo-controlled phase 1 study evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single (SAD) and multiple ascending doses (MAD) of subcutaneous CM512 in healthy adults. Methods: The SAD phase enrolled 40 healthy participants across four sequential cohorts (150, 450, 900, and 1200 mg), randomized 4:1 to receive subcutaneous CM512 or placebo per cohort. The MAD phase enrolled 24 participants across two sequential cohorts (150 and 600 mg biweekly), randomized 2:1 per cohort. The primary endpoint was safety and tolerability; secondary endpoints included PK, PD, and immunogenicity. Results: CM512 was well tolerated. Treatment-emergent adverse events (TEAEs) occurred in 71.9% (23/32) and 68.8% (11/16) of CM512 recipients in the SAD and MAD phases, with incidence comparable to placebo. All treatment-related TEAEs were mild or moderate. No serious adverse events, TEAEs leading to withdrawal, or deaths were reported. In the SAD phase, CM512 displayed linear, dose-proportional PK from 150–1200 mg, accompanied by a long terminal half-life (mean range: 58.7-73.6 days). In the MAD phase, biweekly administration resulted in accumulation (mean accumulation ratio: 2.50-3.17), consistent with its long half-life. CM512 significantly reduced free TSLP and IL-13, and sustainedly lowered blood eosinophils, IgE, and thymus activation-regulated chemokine (TARC) levels versus placebo. The incidence of treatment-emergent anti-drug antibodies in healthy participants receiving CM512 was low, at 3.1% (1/32) in the SAD phase and 0% (0/16) in the MAD phase, respectively. Conclusion: CM512 demonstrated favorable safety, linear PK, and low immunogenicity in healthy participants. It significantly reduced free target cytokines and type 2 inflammation biomarkers, supporting further clinical investigation for type 2 inflammatory diseases. Clinical trial registration: https://clinicaltrials.gov/ , identifier NCT06553209.
- Top Cited PapersOpen Access
- 23 March 2026
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 139 (9) , 1337-1345
Artificial intelligence in atopic dermatitis: Current applications and future perspectives
Atopic dermatitis (AD) is a prevalent and burdensome chronic skin disease, with profound effects on patient quality of life. Advancing its diagnosis and management remains a pressing clinical need. Artificial intelligence holds growing promise in addressing this challenge. This review outlines the current landscape of AD and explores the expanding role of AI in its care—from improving diagnostic accuracy and objective severity scoring to predicting therapeutic outcomes and personalizing treatment strategies. While these technologies are poised to transform dermatology practice, their successful integration will depend on overcoming technical and practical barriers through collaborative, interdisciplinary efforts. Further research and thoughtful implementation are essential to translate AI’s potential into better, more precise patient care.
- 23 March 2026
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 139 (9) , 1337-1345
Top Cited PapersOpen AccessArtificial intelligence in atopic dermatitis: Current applications and future perspectives
Atopic dermatitis (AD) is a prevalent and burdensome chronic skin disease, with profound effects on patient quality of life. Advancing its diagnosis and management remains a pressing clinical need. Artificial intelligence holds growing promise in addressing this challenge. This review outlines the current landscape of AD and explores the expanding role of AI in its care—from improving diagnostic accuracy and objective severity scoring to predicting therapeutic outcomes and personalizing treatment strategies. While these technologies are poised to transform dermatology practice, their successful integration will depend on overcoming technical and practical barriers through collaborative, interdisciplinary efforts. Further research and thoughtful implementation are essential to translate AI’s potential into better, more precise patient care.
- Top Cited PapersOpen Access
- 15 May 2025
- Published by Springer Nature in Molecular Biomedicine
- Vol. 6 (1) , 1-28
Autoimmune bullous diseases: pathogenesis and clinical management
Autoimmune bullous diseases (AIBDs) represent a heterogeneous group of immune-mediated disorders characterized by life-threatening blistering of the skin and mucous membranes. This Review synthesizes current understanding of AIBD pathogenesis, clinical phenotypes, diagnostic approaches, and therapeutic strategies, emphasizing recent advancements and translational opportunities. At the core of AIBDs is autoantibody-mediated disruption of structural proteins in the epidermis or basement membrane zone, particularly at desmosomal and hemidesmosomal junctions. Key subtypes, including pemphigus, paraneoplastic pemphigus, pemphigoid, and IgA-related diseases, are distinguished by their target antigens, clinical manifestations, and immunopathological profiles. Diagnostic workflows rely on direct immunofluorescence, and serological assays, yet subtype differentiation remains challenging due to overlapping features. Traditional therapies, such as systemic corticosteroids and immunosuppressants, have improved outcomes but are limited by toxicity. Recent breakthroughs highlight targeted interventions, including B-cell depletion with rituximab, cytokine modulation via dupilumab, and JAK inhibitors for inflammatory pathways. Innovative strategies like chimeric autoantibody receptor T-cell (CAART) therapy further address refractory cases by eliminating autoreactive B cells. Additionally, the Review underscores the emerging role of inflammation-driven mechanisms and the necessity of multidisciplinary care, given AIBDs’ associations with malignancies, autoimmune comorbidities. Despite progress, challenges persist in early diagnosis, personalized therapy optimization, and understanding antigen-specific immune responses. Future directions include refining diagnostic biomarkers, exploring novel targets, and developing precision medicine approaches.
- 15 May 2025
- Published by Springer Nature in Molecular Biomedicine
- Vol. 6 (1) , 1-28
Top Cited PapersOpen AccessAutoimmune bullous diseases: pathogenesis and clinical management
Autoimmune bullous diseases (AIBDs) represent a heterogeneous group of immune-mediated disorders characterized by life-threatening blistering of the skin and mucous membranes. This Review synthesizes current understanding of AIBD pathogenesis, clinical phenotypes, diagnostic approaches, and therapeutic strategies, emphasizing recent advancements and translational opportunities. At the core of AIBDs is autoantibody-mediated disruption of structural proteins in the epidermis or basement membrane zone, particularly at desmosomal and hemidesmosomal junctions. Key subtypes, including pemphigus, paraneoplastic pemphigus, pemphigoid, and IgA-related diseases, are distinguished by their target antigens, clinical manifestations, and immunopathological profiles. Diagnostic workflows rely on direct immunofluorescence, and serological assays, yet subtype differentiation remains challenging due to overlapping features. Traditional therapies, such as systemic corticosteroids and immunosuppressants, have improved outcomes but are limited by toxicity. Recent breakthroughs highlight targeted interventions, including B-cell depletion with rituximab, cytokine modulation via dupilumab, and JAK inhibitors for inflammatory pathways. Innovative strategies like chimeric autoantibody receptor T-cell (CAART) therapy further address refractory cases by eliminating autoreactive B cells. Additionally, the Review underscores the emerging role of inflammation-driven mechanisms and the necessity of multidisciplinary care, given AIBDs’ associations with malignancies, autoimmune comorbidities. Despite progress, challenges persist in early diagnosis, personalized therapy optimization, and understanding antigen-specific immune responses. Future directions include refining diagnostic biomarkers, exploring novel targets, and developing precision medicine approaches.
- Open Access
- 27 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 3015
Construction and Evaluation of an Artificial Intelligence Assistant Decision-Making System Focused on the Treat-to-Target Framework and Full Process Management for Atopic Dermatitis: Study Protocol for a Randomized Controlled Trial
Background/Objectives: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by recurrent rashes and itching, which seriously affects the quality of life of patients and brings a heavy economic burden to society. The treat-to-target (T2T) strategy was proposed to guide optimal use of systemic therapies in patients with moderate to severe AD, and patients’ adherence is emphasized along with combined evaluation from both health providers and patients. While effective treatments for AD are available, non-adherence of treatment is common in clinical practice due to the patients’ unawareness of self-evaluation and lack of concern about the specific follow-up time points in clinics, which leads to the treatment failure and repeated relapse of AD. Methods: This project consists of three parts. First, an artificial intelligence (AI) model for diagnosis and severity grading of AD based on deep learning will be trained. Second, an AI assistant decision-making system (AIADMS) in the form of an app will be developed. Third, we design a prospective, randomized controlled trial to test the hypothesis that the AIADMS with implementation of the T2T could help control the disease progression and improve the clinical outcomes. Results: A total of 232 participants diagnosed with moderate to severe AD will be included and allocated into the app group or the control group. In the app group, participants will be assisted in using the app during the process of management and follow-up at the scheduled time points, including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months, and 12 months after treatment. In the control group, the diagnosis, treatment, and follow-up of participants will be carried out according to the current routine on a face-to-face basis. The primary outcome is the overall efficiency rate of treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI at 12 weeks after treatment, which is calculated as the “Total number of participants with effective treatment of 5 treating objectives/total number of participants *100%”. Spss20.0 software will be used to analyze the data according to the principle of intent to treat. Trial Registration: The protocol was registered at the National Institutes of Health Clinical Trials Registry with the trial registration number NCT06362629 on 11 April 2024. Conclusions: This study aims to improve AD management by integrating advanced technology, patient engagement, and clinician oversight through AIADMS app to achieve treat-to-target (T2T) goals for effective and safe long-term control.
- 27 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (9) , 3015
Open AccessConstruction and Evaluation of an Artificial Intelligence Assistant Decision-Making System Focused on the Treat-to-Target Framework and Full Process Management for Atopic Dermatitis: Study Protocol for a Randomized Controlled Trial
Background/Objectives: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by recurrent rashes and itching, which seriously affects the quality of life of patients and brings a heavy economic burden to society. The treat-to-target (T2T) strategy was proposed to guide optimal use of systemic therapies in patients with moderate to severe AD, and patients’ adherence is emphasized along with combined evaluation from both health providers and patients. While effective treatments for AD are available, non-adherence of treatment is common in clinical practice due to the patients’ unawareness of self-evaluation and lack of concern about the specific follow-up time points in clinics, which leads to the treatment failure and repeated relapse of AD. Methods: This project consists of three parts. First, an artificial intelligence (AI) model for diagnosis and severity grading of AD based on deep learning will be trained. Second, an AI assistant decision-making system (AIADMS) in the form of an app will be developed. Third, we design a prospective, randomized controlled trial to test the hypothesis that the AIADMS with implementation of the T2T could help control the disease progression and improve the clinical outcomes. Results: A total of 232 participants diagnosed with moderate to severe AD will be included and allocated into the app group or the control group. In the app group, participants will be assisted in using the app during the process of management and follow-up at the scheduled time points, including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months, and 12 months after treatment. In the control group, the diagnosis, treatment, and follow-up of participants will be carried out according to the current routine on a face-to-face basis. The primary outcome is the overall efficiency rate of treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI at 12 weeks after treatment, which is calculated as the “Total number of participants with effective treatment of 5 treating objectives/total number of participants *100%”. Spss20.0 software will be used to analyze the data according to the principle of intent to treat. Trial Registration: The protocol was registered at the National Institutes of Health Clinical Trials Registry with the trial registration number NCT06362629 on 11 April 2024. Conclusions: This study aims to improve AD management by integrating advanced technology, patient engagement, and clinician oversight through AIADMS app to achieve treat-to-target (T2T) goals for effective and safe long-term control.
- Top Cited PapersOpen Access
- 10 February 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1541776
Beyond the dichotomy: understanding the overlap between atopic dermatitis and psoriasis
Atopic dermatitis and psoriasis have traditionally been considered distinct inflammatory skin diseases with unique pathogenic mechanisms. However, accumulating evidence suggests significant overlap in their immunological pathways, metabolic features, and microbiome characteristics, challenging this conventional dichotomy. This review comprehensively examines the complex relationship between psoriasis and atopic dermatitis, with particular emphasis on their shared and distinct pathogenic mechanisms. We analyze the immunological networks, metabolic pathways, and microbial factors contributing to their development and progression. The review expands upon the disease spectrum hypothesis and discusses the nomenclature for conditions exhibiting features of both diseases. We critically evaluate the clinical and histopathological characteristics of concomitant psoriasis and atopic dermatitis, highlighting recent advances in molecular diagnostics for accurate disease differentiation. Importantly, we propose standardized diagnostic criteria for psoriasis dermatitis and examine current therapeutic strategies for managing overlapping conditions. Recent developments in targeted therapies and their implications for treatment selection are thoroughly discussed. By synthesizing current evidence and identifying knowledge gaps, this review provides insights into the complex interplay between psoriasis and atopic dermatitis, aiming to guide clinical decision-making and future research directions in this evolving field.
- 10 February 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1541776
Top Cited PapersOpen AccessBeyond the dichotomy: understanding the overlap between atopic dermatitis and psoriasis
Atopic dermatitis and psoriasis have traditionally been considered distinct inflammatory skin diseases with unique pathogenic mechanisms. However, accumulating evidence suggests significant overlap in their immunological pathways, metabolic features, and microbiome characteristics, challenging this conventional dichotomy. This review comprehensively examines the complex relationship between psoriasis and atopic dermatitis, with particular emphasis on their shared and distinct pathogenic mechanisms. We analyze the immunological networks, metabolic pathways, and microbial factors contributing to their development and progression. The review expands upon the disease spectrum hypothesis and discusses the nomenclature for conditions exhibiting features of both diseases. We critically evaluate the clinical and histopathological characteristics of concomitant psoriasis and atopic dermatitis, highlighting recent advances in molecular diagnostics for accurate disease differentiation. Importantly, we propose standardized diagnostic criteria for psoriasis dermatitis and examine current therapeutic strategies for managing overlapping conditions. Recent developments in targeted therapies and their implications for treatment selection are thoroughly discussed. By synthesizing current evidence and identifying knowledge gaps, this review provides insights into the complex interplay between psoriasis and atopic dermatitis, aiming to guide clinical decision-making and future research directions in this evolving field.
- Open Access
- 1 August 2023
- Published by EDP Sciences in E3S Web of Conferences
- Vol. 409, 01016
The Impact of Green Technology Innovation on Capital Cost of Heavy Polluting Enterprises: The Mediating Effect of Carbon Performance
Under the background of the carbon peaking and carbon neutrality goals proposed in 2020, making heavy polluting enterprises realize that low-carbon measures can bring enough economic benefits is conducive to enhancing their enthusiasm to adopt green behaviors. Using data from 320 listed companies in heavily polluting industries from 2006 to 2019 as samples, our study used multiple linear regression to explore the relationship between green technology innovation, carbon performance, board characteristics and cost of capital. Based on these data, we draw the following conclusions: green technology innovation and carbon performance are significantly negatively correlated with capital cost, carbon performance plays a mediating role in the relationship between green technology innovation and capital cost, and board characteristics play a moderating role in the relationship between green technology innovation and carbon performance. These conclusions bring some implications for enterprises to develop and implement low-carbon measures and reduce capital cost.
- 1 August 2023
- Published by EDP Sciences in E3S Web of Conferences
- Vol. 409, 01016
Open AccessThe Impact of Green Technology Innovation on Capital Cost of Heavy Polluting Enterprises: The Mediating Effect of Carbon Performance
Under the background of the carbon peaking and carbon neutrality goals proposed in 2020, making heavy polluting enterprises realize that low-carbon measures can bring enough economic benefits is conducive to enhancing their enthusiasm to adopt green behaviors. Using data from 320 listed companies in heavily polluting industries from 2006 to 2019 as samples, our study used multiple linear regression to explore the relationship between green technology innovation, carbon performance, board characteristics and cost of capital. Based on these data, we draw the following conclusions: green technology innovation and carbon performance are significantly negatively correlated with capital cost, carbon performance plays a mediating role in the relationship between green technology innovation and capital cost, and board characteristics play a moderating role in the relationship between green technology innovation and carbon performance. These conclusions bring some implications for enterprises to develop and implement low-carbon measures and reduce capital cost.
- Open Access
- 26 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11371
Calcium-Based Antimicrobial Peptide Compounds Attenuate DNFB-Induced Atopic Dermatitis-Like Skin Lesions via Th-Cells in BALB/c Mice
Atopic dermatitis (AD) is a chronic and recurrent inflammatory skin disease, characterized by severe itching and recurrent skin lesions. We hypothesized that a novel treatment involving calcium-based antimicrobial peptide compounds (CAPCS), a combination of natural calcium extracted from marine shellfish, and a variety of antimicrobial peptides, may be beneficial for AD. We established a dinitrofluorobenzene (DNFB)-induced AD model in BALB/c mice to test our hypothesis. We observed mouse behavior and conducted histopathological and immunohistochemical analyses on skin lesions before and after CAPCS treatment. We also characterized the changes in the levels of cytokines, inflammatory mediators, and Toll-like receptors (TLRs) in plasma and skin lesions. The results showed that (i) topical application of CAPCS ameliorated AD-like skin lesions and reduced scratching behavior in BALB/c mice; (ii) CAPCS suppressed infiltration of inflammatory cells and inhibited the expression of inflammatory cytokines in AD-like skin lesions; (iii) CAPCS reduced plasma levels of inflammatory cytokines; and (iv) CAPCS inhibited TLR2 and TLR4 protein expression in skin lesions. Topical application of CAPCS exhibits a therapeutic effect on AD by inhibiting inflammatory immune responses via recruiting helper T cells and engaging the TLR2 and TLR4 signaling pathways. Therefore, CAPCS may be useful for the treatment of AD.
- 26 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11371
Open AccessCalcium-Based Antimicrobial Peptide Compounds Attenuate DNFB-Induced Atopic Dermatitis-Like Skin Lesions via Th-Cells in BALB/c Mice
Atopic dermatitis (AD) is a chronic and recurrent inflammatory skin disease, characterized by severe itching and recurrent skin lesions. We hypothesized that a novel treatment involving calcium-based antimicrobial peptide compounds (CAPCS), a combination of natural calcium extracted from marine shellfish, and a variety of antimicrobial peptides, may be beneficial for AD. We established a dinitrofluorobenzene (DNFB)-induced AD model in BALB/c mice to test our hypothesis. We observed mouse behavior and conducted histopathological and immunohistochemical analyses on skin lesions before and after CAPCS treatment. We also characterized the changes in the levels of cytokines, inflammatory mediators, and Toll-like receptors (TLRs) in plasma and skin lesions. The results showed that (i) topical application of CAPCS ameliorated AD-like skin lesions and reduced scratching behavior in BALB/c mice; (ii) CAPCS suppressed infiltration of inflammatory cells and inhibited the expression of inflammatory cytokines in AD-like skin lesions; (iii) CAPCS reduced plasma levels of inflammatory cytokines; and (iv) CAPCS inhibited TLR2 and TLR4 protein expression in skin lesions. Topical application of CAPCS exhibits a therapeutic effect on AD by inhibiting inflammatory immune responses via recruiting helper T cells and engaging the TLR2 and TLR4 signaling pathways. Therefore, CAPCS may be useful for the treatment of AD.
- 4 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (1) , 67-77.e15
GWAS of Chronic Spontaneous Urticaria Reveals Genetic Overlap with Autoimmune Diseases, Not Atopic Diseases
- 4 August 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (1) , 67-77.e15
GWAS of Chronic Spontaneous Urticaria Reveals Genetic Overlap with Autoimmune Diseases, Not Atopic Diseases
- 2 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 2998-3008.e5
Plasma-Derived Exosomes in Chronic Spontaneous Urticaria Induce the Production of Mediators by Human Mast Cells
- 2 June 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 2998-3008.e5
Plasma-Derived Exosomes in Chronic Spontaneous Urticaria Induce the Production of Mediators by Human Mast Cells